Conference Coverage (AACR)

Ovarian Carcinoma Sensitive to Gene Therapy Approaches

Published in Gene Therapy Weekly, May 5th, 1997

The susceptibility of ovarian carcinoma to combination therapies and gene therapy was the subject of intense scrutiny at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California.

Ovarian carcinoma has an extremely low five year survival rate. This is due largely to the advanced state of the disease in most women at the time of diagnosis. Unfortunately, there are not any early diagnostic tests currently available; new and more effective treatment protocols are desperately needed.

To this end, I. Chung and colleagues from the Yale University School of Medicine, Connecticut, and the New York...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-05-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry